Shattuck Labs Prices $75M Public Offering at $4 Per Share

Shattuck Labs, Inc. announced the pricing of a $75 million public offering on June 10, 2026. The clinical-stage biopharmaceutical company sold its shares at $4.00 each. This capital raise is a critical financing event for advancing its pipeline of immuno-oncology therapies. The offering is expected to close on or about June 13, 2026, subject to customary closing conditions.

Context — [why this matters now]

Biotech equity financings have faced a challenging environment throughout 2026, characterized by elevated interest rates and a risk-off sentiment among generalist investors. The Nasdaq Biotechnology Index (NBI) is down approximately 7% year-to-date, underperforming the broader S&P 500. This offering follows a period of heightened volatility for Shattuck's stock, which had traded as high as $6.50 in the prior month. The decision to price at a significant discount to recent trading levels reflects the necessity of securing capital to fund ongoing clinical programs without delay, a common theme for pre-revenue biotech firms in the current macro climate.

The capital is earmarked explicitly for progressing the company's lead asset, SL-172154. This candidate is a bifunctional fusion protein targeting CD47 and SIRPα, a pathway of intense interest in hematologic malignancies. The financing window for companies with assets in early-to-mid stage trials remains narrow, making successful capital raises a key indicator of investor confidence in a program's underlying science. This transaction provides a multi-year runway for Shattuck to generate crucial clinical data readouts.

Data — [what the numbers show]

Shattuck Labs priced its underwritten public offering of 18.75 million shares at $4.00 per share. The gross proceeds to the company are expected to be $75 million before deducting underwriting discounts and commissions and other offering expenses. The offering price represents a 33.3% discount to the stock's closing price of $6.00 on June 9, 2026. The company has granted the underwriters a 30-day option to purchase up to an additional 2.8125 million shares at the public offering price.

Following the announcement, the stock traded down 18% in pre-market activity to $4.90. The company's market capitalization post-offering is approximately $215 million. This financing is comparable in size to recent biotech raises, such as a $70 million offering by a peer oncology-focused firm in April 2026. The deal's structure is a traditional underwritten offering, contrasting with the at-the-market (ATM) facilities many smaller biotechs have used for incremental capital.

Analysis — [what it means for markets / sectors / tickers]

The successful pricing of this offering is a net positive for the broader preclinical and clinical-stage oncology sector, demonstrating that capital remains available for compelling scientific narratives. Companies with similar CD47-targeting platforms, like ALXO and IGMX, may see sympathetic moves as investors reassess the funding viability for early-stage assets. The immediate dilution and share price decline are a direct negative for existing equity holders, but the avoidance of a funding crisis is a fundamental positive.

A primary risk is the highly competitive nature of the CD47 space, with several large-cap pharma companies developing advanced candidates. The capital raised must be efficiently deployed to achieve clear clinical milestones that de-risk the program further. Institutional healthcare funds are the most likely buyers of this offering, positioning for a binary outcome on future data releases. Retail ownership is likely to decrease post-offering due to the dilutive effect and the typical investor base for such financings.

Outlook — [what to watch next]

The immediate catalyst is the official closing of the offering, expected around June 13, 2026. Investor focus will then shift to the clinical timeline for SL-172154. The next material data readout from the Phase 1 trial in ovarian cancer and myelodysplastic syndromes (MDS) is anticipated in the fourth quarter of 2026. These results will be the primary driver of shareholder value for the next six to nine months.

Key levels to watch for the stock include the $4.00 offering price as a psychological support level and the 50-day simple moving average, currently near $5.25, as resistance. The company's cash burn rate will be scrutinized in the next quarterly earnings report on August 10, 2026. Positive clinical data could propel the stock back toward its 52-week high of $8.50, while disappointing results would put significant pressure on the newly established support level.

Frequently Asked Questions

What does a public offering mean for existing Shattuck Labs shareholders?

Existing shareholders experience immediate dilution as the total number of outstanding shares increases. This often causes a short-term decline in the share price, as seen with this offering. However, the capital raised prevents the company from facing a cash shortage, which is a more severe risk. The long-term value for shareholders now depends almost entirely on the success of the clinical programs funded by this capital.

How does this biotech financing compare to others in 2026?

The $75 million size is median for a single-asset clinical-stage biotech in the current market. The significant discount to the market price was necessary to secure investor interest amid a cautious backdrop. Many comparable offerings in 2026 have included warrants or other structured elements to attract buyers, making this a relatively straightforward transaction.

What is the significance of targeting CD47 in cancer therapy?

The CD47 protein is often overexpressed on cancer cells, acting as a 'do not eat me' signal to the immune system. Blocking this signal allows the body's macrophages to recognize and destroy cancer cells. It is a validated but competitive oncology target, with several programs in late-stage development, making clear differentiation and strong clinical data imperative for Shattuck's success.

Bottom Line

Shattuck Labs secured essential funding at a dilutive price to advance its clinical assets in a challenging biotech market.

Disclaimer: This article is for informational purposes only and does not constitute investment advice. CFD trading carries high risk of capital loss.